Literature DB >> 9829155

A practical guide to the management and prevention of migraine.

H C Diener1, H Kaube, V Limmroth.   

Abstract

Migraine is a paroxysmal disorder with attacks of headache, nausea, vomiting, photo- and phonophobia and malaise. Mild migraine attacks are treated with antiemetics followed by analgesics such as aspirin (acetylsalicylic acid), paracetamol (acetaminophen) or nonsteroidal anti-inflammatory drugs (NSAIDs). Moderate to severe attacks are treated by antiemetics combined with ergotamine or dihydroergotamine. Sumatriptan, a specific serotonin 5-HT1B/D receptor agonist, is used if attacks do not respond to ergotamine or if intolerable adverse effects occur. The new migraine drugs zolmitriptan, naratriptan, rizatriptan and eletriptan differ in their pharmacological profile from sumatriptan, but this translates into only minor differences in efficacy, headache recurrence and adverse effects. Migraine prophylaxis should be implemented when more than 3 attacks occur per month, if attacks do not respond to acute treatment or if the adverse effects of acute treatment are severe. Substances with proven efficacy include the beta-blockers metoprolol and propranolol and the calcium antagonist flunarizine. Drugs less effective or those with unpleasant adverse effects are the serotonin receptor antagonists (pizotifen, methysergide and lisuride), dihydroergotamine, cyclandelate, NSAIDs, valproic acid (sodium valproate) and amitriptyline. The efficacy of aspirin or magnesium is still under evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829155     DOI: 10.2165/00003495-199856050-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  71 in total

1.  Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial.

Authors:  M van Dusseldorp; M B Katan
Journal:  BMJ       Date:  1990-06-16

2.  Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.

Authors:  H C Diener; M Föh; C Iaccarino; P Wessely; H Isler; H Strenge; M Fischer; W Wedekind; Z Taneri
Journal:  Cephalalgia       Date:  1996-10       Impact factor: 6.292

3.  Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?

Authors:  M L Hämäläinen; K Hoppu; P Santavuori
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

4.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

5.  Acetylsalicylic acid vs. metoprolol in migraine prophylaxis--a double-blind cross-over study.

Authors:  K H Grotemeyer; H W Scharafinski; H P Schlake; I W Husstedt
Journal:  Headache       Date:  1990-10       Impact factor: 5.887

6.  Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks.

Authors:  A May; H J Gijsman; A Wallnöfer; R Jones; H C Diener; M D Ferrari
Journal:  Pain       Date:  1996-10       Impact factor: 6.961

7.  A gene for familial hemiplegic migraine maps to chromosome 19.

Authors:  A Joutel; M G Bousser; V Biousse; P Labauge; H Chabriat; A Nibbio; J Maciazek; B Meyer; M A Bach; J Weissenbach
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

8.  Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.

Authors:  M G Buzzi; M A Moskowitz; S J Peroutka; B Byun
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

9.  A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.

Authors: 
Journal:  Eur Neurol       Date:  1992       Impact factor: 1.710

10.  Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo.

Authors:  B Mikkelsen; K K Pedersen; L V Christiansen
Journal:  Acta Neurol Scand       Date:  1986-04       Impact factor: 3.209

View more
  18 in total

1.  Migraine prophylaxis in adult patients.

Authors:  D Parsekyan
Journal:  West J Med       Date:  2000-11

Review 2.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  The pharmacological management of migraine, part 2: preventative therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-08

4.  Therapy of Migraine Headache in Cancer Patients.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

5.  Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.

Authors:  Mark Sculpher; David Millson; David Meddis; Lynne Poole
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 6.  Frovatriptan.

Authors:  S E Easthope; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

7.  Effects of betaxolol and flunarizine on visual fields and intraocular pressure in patients with migraine.

Authors:  Alper Yarangümeli; Selçuk Comoglu; Ozlem Gürbüz Köz; Atilla Halil Elhan; Gülcan Kural
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

Review 8.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate.

Authors:  Mansoureh Togha; Togha Mansoureh; Masoud Rahmat Jirde; Kiafar Nilavari; Hosein Ashrafian; Soodeh Razeghi; Leila Kohan
Journal:  J Headache Pain       Date:  2008-02-20       Impact factor: 7.277

10.  Comparative Study of Different Combinational Mucoadhesive Formulations of Sumatriptan-Metoclopramide.

Authors:  Mitra Jelvehgari; Hadi Valizadeh; Sanam Ziapour; Mahdieh Rahmani; Seyed Hassan Montazam; Saieede Soltani
Journal:  Adv Pharm Bull       Date:  2016-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.